STORM Therapeutics Expands R&D Leadership Team
- Matthew Fyfe joins as Senior Vice President of Therapeutics
- Beth Thomas promoted to Vice President of Medicinal Chemistry
10 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces the appointment of Matthew Fyfe as Senior Vice President of Therapeutics and the promotion of Beth Thomas to Vice President of Medicinal Chemistry.
